Prolonged response to gefitinib in bone metastasis.
Satoh
Hiroaki
H
Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki 305-8575, Japan. hirosato@md.tsukuba.ac.jp
Ishikawa
Hiroichi
H
Ohara
Gen
G
Kikuchi
Norihiro
N
Sekizawa
Kiyohisa
K
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001416:Back Pain; D016190:Carboplatin / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D013125:Spinal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000556:secondary*; D013997:Time Factors
D000972:Antineoplastic Agents, Phytogenic; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D016190:Carboplatin; D017239:Paclitaxel; D000077156:Gefitinib